Gilead Sciences (NASDAQ:GILD) Hits New 12-Month High – Time to Buy?

Gilead Sciences, Inc. (NASDAQ:GILD)’s share price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $99.37 and last traded at $99.24, with a volume of 1879395 shares changing hands. The stock had previously closed at $97.20.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. UBS Group raised their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Bank of America reissued a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 10th. Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Citigroup assumed coverage on Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price objective on the stock. Finally, Wells Fargo & Company raised their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Gilead Sciences Stock Performance

The stock’s 50 day moving average is $92.71 and its two-hundred day moving average is $86.32. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The firm has a market cap of $124.19 billion, a P/E ratio of 1,107.22, a PEG ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.29 earnings per share. As a group, equities analysts predict that Gilead Sciences, Inc. will post 4.34 EPS for the current year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 572,824 shares of company stock valued at $53,611,715. Corporate insiders own 0.29% of the company’s stock.

Institutional Trading of Gilead Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of GILD. HHM Wealth Advisors LLC lifted its stake in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the last quarter. nVerses Capital LLC bought a new stake in shares of Gilead Sciences in the 3rd quarter worth approximately $25,000. YANKCOM Partnership bought a new stake in shares of Gilead Sciences during the 4th quarter valued at about $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $29,000. Finally, Valued Wealth Advisors LLC lifted its position in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.